Clinical-stage biopharmaceutical company Praxis Precision Medicines rose more than 2% before the market on Monday after BTIG listed its stock as the preferred target for 2026 and raised its target price. The new price target was raised from $507 to $843, meaning there is more than 213% potential upside for the stock.

Clinical-stage biopharmaceutical company Praxis Precision Medicines rose more than 2% before the market on Monday after BTIG listed its stock as the preferred target for 2026 and raised its target price. The new price target was raised from $507 to $843, meaning there is more than 213% potential upside for the stock.